Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas tranplantation

Enver Akalin, Scott Ames, Vinita Sehgal, Barbara Murphy, Jonathan S. Bromberg

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Hepatitis B virus core antibody (HBcAb) or surface antigen (HBsAg)-positive organ donors have the potential to transmit infection to transplant recipients. We investigated the safety of using HBcAb(+) or HBsAg(+) donors in kidney or pancreas transplant recipients with 1 yr lamivudine prophylaxis. While HBsAb(-) recipients of HBcAb(+) donors received prophylaxis, HBsAb(+) recipients did not. HBsAg(+) organs were only used in patients who were both HBcAb and HBsAb(+). Forty-six patients received HBcAb(+) and four received HBsAg(+) organs (47 kidney, two pancreas, and one kidney/pancreas). All but one recipient were HBsAg(-), 25 were HBsAb(+), and 19 HBcAb(+). During a median 36 months of follow-up (range 6-66 months), with 43 of a total 50 patients having at least 1 yr follow-up and were off lamivudine, and none of the patients developed hepatitis B viremia or seroconversion to HBsAg or HBsAb(+). These results suggest that HBcAb(+) or HBsAg(+) organs can be used safely in selected recipients with lamivudine prophylaxis without requiring hepatitis B immunglobulin.

Original languageEnglish (US)
Pages (from-to)364-366
Number of pages3
JournalClinical Transplantation
Volume19
Issue number3
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Hepatitis B Antibodies
Surface Antigens
Pancreas
Tissue Donors
Kidney
Safety
Lamivudine
Hepatitis B
Viremia
Infection

Keywords

  • Hepatitis B core antibody
  • Kidney transplantation
  • Lamivudine

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas tranplantation. / Akalin, Enver; Ames, Scott; Sehgal, Vinita; Murphy, Barbara; Bromberg, Jonathan S.

In: Clinical Transplantation, Vol. 19, No. 3, 06.2005, p. 364-366.

Research output: Contribution to journalArticle

Akalin, Enver ; Ames, Scott ; Sehgal, Vinita ; Murphy, Barbara ; Bromberg, Jonathan S. / Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas tranplantation. In: Clinical Transplantation. 2005 ; Vol. 19, No. 3. pp. 364-366.
@article{89da47c68a614dafab6a5745ecd75828,
title = "Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas tranplantation",
abstract = "Hepatitis B virus core antibody (HBcAb) or surface antigen (HBsAg)-positive organ donors have the potential to transmit infection to transplant recipients. We investigated the safety of using HBcAb(+) or HBsAg(+) donors in kidney or pancreas transplant recipients with 1 yr lamivudine prophylaxis. While HBsAb(-) recipients of HBcAb(+) donors received prophylaxis, HBsAb(+) recipients did not. HBsAg(+) organs were only used in patients who were both HBcAb and HBsAb(+). Forty-six patients received HBcAb(+) and four received HBsAg(+) organs (47 kidney, two pancreas, and one kidney/pancreas). All but one recipient were HBsAg(-), 25 were HBsAb(+), and 19 HBcAb(+). During a median 36 months of follow-up (range 6-66 months), with 43 of a total 50 patients having at least 1 yr follow-up and were off lamivudine, and none of the patients developed hepatitis B viremia or seroconversion to HBsAg or HBsAb(+). These results suggest that HBcAb(+) or HBsAg(+) organs can be used safely in selected recipients with lamivudine prophylaxis without requiring hepatitis B immunglobulin.",
keywords = "Hepatitis B core antibody, Kidney transplantation, Lamivudine",
author = "Enver Akalin and Scott Ames and Vinita Sehgal and Barbara Murphy and Bromberg, {Jonathan S.}",
year = "2005",
month = "6",
doi = "10.1111/j.1399-0012.2005.00350.x",
language = "English (US)",
volume = "19",
pages = "364--366",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas tranplantation

AU - Akalin, Enver

AU - Ames, Scott

AU - Sehgal, Vinita

AU - Murphy, Barbara

AU - Bromberg, Jonathan S.

PY - 2005/6

Y1 - 2005/6

N2 - Hepatitis B virus core antibody (HBcAb) or surface antigen (HBsAg)-positive organ donors have the potential to transmit infection to transplant recipients. We investigated the safety of using HBcAb(+) or HBsAg(+) donors in kidney or pancreas transplant recipients with 1 yr lamivudine prophylaxis. While HBsAb(-) recipients of HBcAb(+) donors received prophylaxis, HBsAb(+) recipients did not. HBsAg(+) organs were only used in patients who were both HBcAb and HBsAb(+). Forty-six patients received HBcAb(+) and four received HBsAg(+) organs (47 kidney, two pancreas, and one kidney/pancreas). All but one recipient were HBsAg(-), 25 were HBsAb(+), and 19 HBcAb(+). During a median 36 months of follow-up (range 6-66 months), with 43 of a total 50 patients having at least 1 yr follow-up and were off lamivudine, and none of the patients developed hepatitis B viremia or seroconversion to HBsAg or HBsAb(+). These results suggest that HBcAb(+) or HBsAg(+) organs can be used safely in selected recipients with lamivudine prophylaxis without requiring hepatitis B immunglobulin.

AB - Hepatitis B virus core antibody (HBcAb) or surface antigen (HBsAg)-positive organ donors have the potential to transmit infection to transplant recipients. We investigated the safety of using HBcAb(+) or HBsAg(+) donors in kidney or pancreas transplant recipients with 1 yr lamivudine prophylaxis. While HBsAb(-) recipients of HBcAb(+) donors received prophylaxis, HBsAb(+) recipients did not. HBsAg(+) organs were only used in patients who were both HBcAb and HBsAb(+). Forty-six patients received HBcAb(+) and four received HBsAg(+) organs (47 kidney, two pancreas, and one kidney/pancreas). All but one recipient were HBsAg(-), 25 were HBsAb(+), and 19 HBcAb(+). During a median 36 months of follow-up (range 6-66 months), with 43 of a total 50 patients having at least 1 yr follow-up and were off lamivudine, and none of the patients developed hepatitis B viremia or seroconversion to HBsAg or HBsAb(+). These results suggest that HBcAb(+) or HBsAg(+) organs can be used safely in selected recipients with lamivudine prophylaxis without requiring hepatitis B immunglobulin.

KW - Hepatitis B core antibody

KW - Kidney transplantation

KW - Lamivudine

UR - http://www.scopus.com/inward/record.url?scp=19044386801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19044386801&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2005.00350.x

DO - 10.1111/j.1399-0012.2005.00350.x

M3 - Article

C2 - 15877799

AN - SCOPUS:19044386801

VL - 19

SP - 364

EP - 366

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 3

ER -